 Sameer Nath
Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 17 | 2019 | 389 | 2.610 |
Why?
| | Prostatic Neoplasms | 6 | 2019 | 1044 | 1.090 |
Why?
| | Brain Neoplasms | 9 | 2018 | 1267 | 1.030 |
Why?
| | Lung Neoplasms | 11 | 2019 | 2527 | 0.910 |
Why?
| | Radiotherapy, Intensity-Modulated | 7 | 2019 | 137 | 0.820 |
Why?
| | Radiation Oncology | 3 | 2021 | 85 | 0.800 |
Why?
| | Oncology Nursing | 1 | 2021 | 28 | 0.670 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 6 | 2019 | 1111 | 0.650 |
Why?
| | Radiation Dosage | 3 | 2019 | 188 | 0.630 |
Why?
| | Chemoradiotherapy | 2 | 2019 | 230 | 0.630 |
Why?
| | Organs at Risk | 1 | 2019 | 35 | 0.610 |
Why?
| | Immunity, Cellular | 1 | 2019 | 269 | 0.530 |
Why?
| | Brachytherapy | 2 | 2017 | 129 | 0.510 |
Why?
| | Positron-Emission Tomography | 4 | 2018 | 304 | 0.440 |
Why?
| | Radiotherapy Dosage | 9 | 2017 | 281 | 0.440 |
Why?
| | Curriculum | 1 | 2021 | 1009 | 0.420 |
Why?
| | Mycosis Fungoides | 1 | 2014 | 60 | 0.420 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 1742 | 0.400 |
Why?
| | Aged, 80 and over | 14 | 2019 | 7677 | 0.390 |
Why?
| | Kaplan-Meier Estimate | 5 | 2019 | 896 | 0.370 |
Why?
| | Four-Dimensional Computed Tomography | 1 | 2011 | 38 | 0.350 |
Why?
| | Aged | 23 | 2019 | 24024 | 0.340 |
Why?
| | Radiography, Interventional | 1 | 2011 | 119 | 0.320 |
Why?
| | Urogenital System | 1 | 2009 | 17 | 0.320 |
Why?
| | Particle Accelerators | 1 | 2009 | 9 | 0.310 |
Why?
| | Multivariate Analysis | 4 | 2019 | 1482 | 0.300 |
Why?
| | Proportional Hazards Models | 3 | 2019 | 1229 | 0.290 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2015 | 1057 | 0.290 |
Why?
| | Radiation Injuries | 1 | 2009 | 147 | 0.290 |
Why?
| | Middle Aged | 18 | 2019 | 33604 | 0.270 |
Why?
| | Follow-Up Studies | 11 | 2018 | 5112 | 0.270 |
Why?
| | Magnetic Resonance Imaging | 7 | 2018 | 3637 | 0.260 |
Why?
| | Gastrointestinal Tract | 1 | 2009 | 204 | 0.260 |
Why?
| | Male | 24 | 2021 | 68260 | 0.250 |
Why?
| | Skin Neoplasms | 1 | 2014 | 837 | 0.250 |
Why?
| | Radiation Pneumonitis | 2 | 2017 | 31 | 0.250 |
Why?
| | Glioma | 1 | 2010 | 407 | 0.240 |
Why?
| | Small Cell Lung Carcinoma | 2 | 2018 | 115 | 0.240 |
Why?
| | Adult | 15 | 2021 | 38201 | 0.220 |
Why?
| | Radiotherapy | 2 | 2017 | 207 | 0.220 |
Why?
| | Uterine Cervical Neoplasms | 3 | 2013 | 282 | 0.210 |
Why?
| | Treatment Outcome | 10 | 2019 | 10923 | 0.200 |
Why?
| | Humans | 34 | 2021 | 138651 | 0.200 |
Why?
| | Cranial Irradiation | 3 | 2018 | 85 | 0.180 |
Why?
| | Female | 21 | 2021 | 73763 | 0.180 |
Why?
| | Radiotherapy, Computer-Assisted | 2 | 2010 | 12 | 0.160 |
Why?
| | Multimodal Imaging | 2 | 2018 | 117 | 0.160 |
Why?
| | Survival Analysis | 5 | 2018 | 1309 | 0.160 |
Why?
| | Retrospective Studies | 11 | 2019 | 15909 | 0.160 |
Why?
| | Neoplasm Metastasis | 2 | 2019 | 666 | 0.150 |
Why?
| | Education, Nursing | 1 | 2021 | 94 | 0.150 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2018 | 252 | 0.150 |
Why?
| | Brain | 2 | 2010 | 2792 | 0.150 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 1235 | 0.150 |
Why?
| | Lymphopenia | 1 | 2019 | 66 | 0.150 |
Why?
| | Tumor Hypoxia | 1 | 2018 | 7 | 0.140 |
Why?
| | Leukocyte Count | 1 | 2019 | 326 | 0.140 |
Why?
| | Neutropenia | 1 | 2019 | 157 | 0.140 |
Why?
| | Needs Assessment | 1 | 2021 | 379 | 0.140 |
Why?
| | Immune System | 1 | 2019 | 181 | 0.140 |
Why?
| | CTLA-4 Antigen | 1 | 2018 | 98 | 0.140 |
Why?
| | Circulating Tumor DNA | 1 | 2018 | 31 | 0.140 |
Why?
| | Disease-Free Survival | 1 | 2019 | 704 | 0.130 |
Why?
| | Absorbable Implants | 1 | 2017 | 36 | 0.130 |
Why?
| | Ultrasonography | 2 | 2018 | 745 | 0.130 |
Why?
| | Lymphocytes | 1 | 2019 | 395 | 0.130 |
Why?
| | Disease Progression | 3 | 2019 | 2749 | 0.130 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2013 | 638 | 0.130 |
Why?
| | Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2017 | 77 | 0.130 |
Why?
| | Neoplasm Staging | 6 | 2018 | 1372 | 0.130 |
Why?
| | Androgen Antagonists | 1 | 2017 | 93 | 0.130 |
Why?
| | Antibodies | 1 | 2018 | 404 | 0.120 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 520 | 0.120 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2017 | 375 | 0.120 |
Why?
| | Prognosis | 5 | 2018 | 3984 | 0.120 |
Why?
| | Propensity Score | 1 | 2017 | 316 | 0.120 |
Why?
| | Heart | 1 | 2019 | 611 | 0.120 |
Why?
| | Time Factors | 3 | 2018 | 6851 | 0.120 |
Why?
| | Age Factors | 2 | 2014 | 3256 | 0.110 |
Why?
| | Dose-Response Relationship, Radiation | 2 | 2018 | 142 | 0.110 |
Why?
| | United States | 6 | 2021 | 14938 | 0.110 |
Why?
| | Odds Ratio | 1 | 2017 | 1044 | 0.110 |
Why?
| | Neoadjuvant Therapy | 1 | 2017 | 412 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 4 | 2018 | 2698 | 0.110 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 196 | 0.110 |
Why?
| | Treatment Failure | 2 | 2015 | 351 | 0.110 |
Why?
| | Risk Factors | 4 | 2017 | 10252 | 0.100 |
Why?
| | Marital Status | 1 | 2014 | 45 | 0.100 |
Why?
| | Cisplatin | 2 | 2013 | 327 | 0.100 |
Why?
| | Neutrophils | 1 | 2019 | 1274 | 0.100 |
Why?
| | Salvage Therapy | 2 | 2015 | 151 | 0.100 |
Why?
| | SEER Program | 1 | 2014 | 220 | 0.100 |
Why?
| | Young Adult | 5 | 2017 | 13305 | 0.090 |
Why?
| | Logistic Models | 1 | 2017 | 2065 | 0.090 |
Why?
| | Databases, Factual | 1 | 2017 | 1415 | 0.090 |
Why?
| | Melanoma | 1 | 2018 | 756 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 2 | 2010 | 1323 | 0.090 |
Why?
| | Biomarkers, Tumor | 1 | 2018 | 1224 | 0.090 |
Why?
| | Cervix Uteri | 1 | 2011 | 52 | 0.080 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2011 | 116 | 0.080 |
Why?
| | Cone-Beam Computed Tomography | 1 | 2009 | 27 | 0.080 |
Why?
| | Prostatectomy | 1 | 2009 | 102 | 0.080 |
Why?
| | Cause of Death | 1 | 2011 | 433 | 0.080 |
Why?
| | Survival Rate | 4 | 2016 | 1935 | 0.070 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2009 | 215 | 0.070 |
Why?
| | Registries | 1 | 2017 | 2073 | 0.070 |
Why?
| | Tumor Burden | 1 | 2010 | 309 | 0.070 |
Why?
| | Postoperative Period | 1 | 2009 | 355 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 5803 | 0.070 |
Why?
| | Image-Guided Biopsy | 2 | 2018 | 39 | 0.070 |
Why?
| | Sex Factors | 1 | 2014 | 2044 | 0.070 |
Why?
| | Neurosurgical Procedures | 1 | 2009 | 204 | 0.070 |
Why?
| | Healthcare Disparities | 1 | 2014 | 659 | 0.070 |
Why?
| | Imaging, Three-Dimensional | 1 | 2011 | 564 | 0.070 |
Why?
| | Diagnostic Imaging | 1 | 2009 | 320 | 0.070 |
Why?
| | Incidence | 1 | 2014 | 2747 | 0.060 |
Why?
| | Neoplasm Grading | 2 | 2018 | 305 | 0.060 |
Why?
| | Comorbidity | 1 | 2011 | 1656 | 0.060 |
Why?
| | Head and Neck Neoplasms | 1 | 2011 | 549 | 0.060 |
Why?
| | Lung | 1 | 2019 | 4106 | 0.060 |
Why?
| | Neoplasms | 2 | 2010 | 2681 | 0.060 |
Why?
| | Severity of Illness Index | 1 | 2009 | 2851 | 0.040 |
Why?
| | Physicians | 1 | 2009 | 932 | 0.040 |
Why?
| | Prospective Studies | 3 | 2018 | 7554 | 0.040 |
Why?
| | Automation | 1 | 2020 | 99 | 0.040 |
Why?
| | Patient Positioning | 1 | 2020 | 69 | 0.040 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 2 | 2011 | 138 | 0.040 |
Why?
| | False Positive Reactions | 1 | 2018 | 124 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2018 | 433 | 0.030 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 216 | 0.030 |
Why?
| | Child, Preschool | 1 | 2010 | 11158 | 0.030 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 190 | 0.030 |
Why?
| | Radiometry | 1 | 2015 | 50 | 0.030 |
Why?
| | Risk Assessment | 2 | 2017 | 3433 | 0.030 |
Why?
| | Radiology | 1 | 2017 | 164 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 539 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1482 | 0.030 |
Why?
| | Immunotherapy | 1 | 2018 | 634 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2017 | 1941 | 0.020 |
Why?
| | Adolescent | 1 | 2010 | 21564 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2844 | 0.020 |
Why?
| | Child | 1 | 2010 | 21921 | 0.020 |
Why?
| | Motion | 1 | 2011 | 99 | 0.020 |
Why?
| | Vinblastine | 1 | 2010 | 71 | 0.020 |
Why?
| | Radiographic Image Enhancement | 1 | 2010 | 57 | 0.020 |
Why?
| | Decision Making | 1 | 2017 | 948 | 0.020 |
Why?
| | Carboplatin | 1 | 2010 | 146 | 0.020 |
Why?
| | Utilization Review | 1 | 2009 | 41 | 0.020 |
Why?
| | Algorithms | 1 | 2017 | 1740 | 0.020 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2009 | 19 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2010 | 328 | 0.020 |
Why?
| | Hysterectomy | 1 | 2010 | 136 | 0.020 |
Why?
| | Fluorouracil | 1 | 2010 | 204 | 0.020 |
Why?
| | Rectum | 1 | 2010 | 189 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2010 | 565 | 0.020 |
Why?
| | Urinary Bladder | 1 | 2010 | 187 | 0.020 |
Why?
| | Equipment Design | 1 | 2009 | 519 | 0.020 |
Why?
| | Cohort Studies | 1 | 2018 | 5697 | 0.020 |
Why?
| | Radiography | 1 | 2009 | 841 | 0.020 |
Why?
| | Data Collection | 1 | 2009 | 657 | 0.020 |
Why?
| | Mutation | 1 | 2018 | 3987 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2013 | 3523 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2010 | 2152 | 0.010 |
Why?
|
|
Nath's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|